학술논문
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Document Type
Article
Author
Rummel, Mothias J.; Niederle, Norbert; Maschmeyer, Georg; Banat, G. Andre; von Grünhagen, Ulrich; Losem, Christoph; Kofahl-Krause, Dorothea; Heil, Gerhard; Welslau, Manfred; Balser, Christina; Kaiser, Ulrich; Weidmann, Eckhart; Dürk, Heinz; Balló, Harold; Stauch, Martina; Roller, Fritz; Barth, Juergen; Hoelzer, Dieter; Hinke, Axel; Brugger, Wolfram
Source
Subject
*RITUXIMAB
*CYCLOPHOSPHAMIDE
*DOXORUBICIN
*VINCRISTINE
*LYMPHOMA treatment
*ERYTHEMA
*
*
*
*
*
Language
ISSN
0140-6736
Abstract
The article presents a study comparing bendamustine plus rituximab and cyclophosphamide, doxorubicin, vincristine, and prenisone (CHOP) plus rituximab in the treatment of patients with indolent and mantle-cell lymphomas. It showed that erythematous skin reactions were mostly observed in patients in the bendamustine plus retuximab group compared to those in the R-CHOP group. Result demonstrate the increased progression-free survival and less toxic effects in bendamustine plus retoximab. INSET: Panel: Research in context.